The cost of treatment and care for people living with HIV infection: Implications of published studies, 1999-2008

Current Opinion in HIV and AIDS

Volumn 5, Issue 3, 2010, Pages 215-224

  Beck, Eduard J ^a   Harling, Guy ^a   Gerbase, Sofia ^a   DeLay, Paul ^a  

^a UNAIDS   (Switzerland)

Author keywords

ART; Population costs; Regional and country comparisons; Use and cost HIV treatment and care services

Indexed keywords

COST EFFECTIVENESS ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; MEDICAL SERVICE; OUTPATIENT CARE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME;

AFRICA; ASIA; EUROPE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; NORTH AMERICA;

EID: 77951076575     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833860e9     Document Type: Review

References (134)

1. Beck EJ, Walensky RP. The outcome and impact of ten years of HAART. In: Zuniga JM, Whiteside A, Ghaziani A, Bartlett JG, editors. A decade of HAART. Oxford, UK: Oxford University Press; 2008. pp. 45-62.
2. UNAIDS.09 AIDS Epidemic Update. Geneva: UNAIDS, WHO; 2009. http:// data.unaids.org/pub/Report/2009/JC1700-Epi-Update-2009-en.pdf. [Accessed January 2010]
3. UNAIDS. What countries need: investments needed for 2010 targets. Geneva: UNAIDS; 2009. http://data.unaids.org/pub/Report/2009/ JC1681-what-countries- need-en.pdf. [Accessed January 2010]
4. General Assembly 60/262. Political Declaration on HIV/AIDS; 15 June 2006; United Nations, New York USA. http://data.unaids.org/pub/Report/ 2006/20060615-HLM-PoliticalDeclaration-ARES60262-en.pdf. [Accessed January 2010]
5. General Assembly 55/2. United Nations Millennium Declaration; 8 September 2000; United Nations, New York USA. http://www.un.org/millennium/ declaration/ares552e.htm. [Accessed January 2010]
6. Beck EJ, Santas X, DeLay P. Why and how to monitor the cost and evaluate the cost effectiveness of HIV services in countries. AIDS 2008; 22 (Suppl 1): S75-S85.
7. Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001; 19:13-39.
8. Youle M, Trueman P, Simpson K. Health economics in HIV disease: a review of the European literature. Pharmacoeconomics 1999; 15 (Suppl 1):1-12.
9. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis 2006; 6:171-177.
10. Harling G, Wood R, Beck EJ. Efficiency of intervention in HIV infection, 1994-2004. Dis Manag Health Outcomes 2005; 13:371-394.
11. Beck EJ, Miners AH. Effectiveness and efficiency in the delivery of HIV services: economic and related considerations. In: Gazzard B, Johnson M, Miles A, editors. The effective management of HIV disease. London: Aesculapius Medical Press; 2001. pp. 113-138.
12. World Bank. World Development Indicators Online; Washington, District of Columbia: World Bank. http://publications.worldbank.org/WDI/. [Accessed January 2010]
13. Giraudon I, Leroy V, Msellati P, et al. The costs of treating HIV-infected children in Abidjan, Ivory Coast, 1996-1997. Sante Publique 1999; 9:277-281.
14. Djohan G, Kouakoussui A, Msellati P. Direct cost related to management and care provision for HIV-infected children in the asymptomatic stage in Abidjan, Cote d'Ivoire. Sante Publique 2005; 17:627-636.
15. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost- effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cô te d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-1308.
16. Haile B. Affordability of home-based care for HIV/AIDS. S Afr Med J 2000; 90:690-691.
17. Uys L, Hensher M. The cost of home-based terminal care for people with AIDS in South Africa. S Afr Med J 2002; 92:624-628.
18. Yengopal V, Naidoo S. Cost of inpatient care for HIV-positive patients at Red Cross Children's Hospital, Cape Town. S Afr J HIV Med 2004; 17:32-40.
19. Deghaye N, Pawinski RA, Desmond C. Financial and economic costs of scaling up the provision of HAART to HIV-infected healthcare workers in KwaZulu-Natal. S Afr Med J 2006; 96:140-143.
20. Veenstra N, Oyier A. The burden of HIV-related illness on outpatient health services in KwaZulu-Natal, South Africa. AIDS Care 2006; 18:262-268.
21. Badri M, Cleary S, Maartens G, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? a South African cost-effectiveness study. Antivir Ther 2006; 11:63-72.
22. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006; 3:e4.
23. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Eff Resour Alloc 2006; 4:20.
24. Harling G, Wood R. The evolving cost of HIV in South Africa: changes in healthcare cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 2007; 45:348-354.
25. Thomas LS, Manning A, Holmes CB, et al. Comparative costs of inpatient care for HIV-infected and uninfected children and adults in Soweto, South Africa. J Acquir Immune Defic Syndr 2007; 46:410-416.
26. Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health 2008; 13:1005-1015.
27. Hansen K, Chapman G, Chitsike I, et al. The costs of HIV/AIDS care at government hospitals in Zimbabwe. Health Pol Plann 2000; 15:432-440.
28. Guinness L, Arthur G, Bhatt SM, et al. Costs of hospital care for HIV-positive and HIV-negative patients at Kenyatta National Hospital, Nairobi, Kenya. AIDS 2002; 16:901-908.
29. Pitter C, Kahn JG, Marseille E, et al. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. J Acquir Immune Defic Syndr 2007; 44:336-343.
30. Hounton SH, Akonde A, Zannou DM, et al. Costing universal access of highly active antiretroviral therapy in Benin. AIDS Care 2008; 20:582-587.
31. Kitajima T, Kobayashi Y, Chaipah W, et al. Costs of medical services for patients with HIV/AIDS in Khon Kaen. Thailand AIDS 2003; 17:2375-2381.
32. Pansatiankul B, Bunnag T, Leowsrisook P. Medical and nonmedical expenses for treating babies born to HIV-infected and non-HIV-infected mothers. J Med Assoc Thai 2003; 86 (Suppl 3):S719-S726.
33. RatanasuwanW, Anekthananon T, Techasathit W, et al. Estimated economic losses of hospitalized AIDS patients at Siriraj hospital from January 2003 to December 2003: time for aggressive voluntary counseling and HIV testing. J Med Assoc Thai 2005; 88:335-339.
34. Over M, Revenga A, Masaki E, et al. The economics of effective AIDS treatment in Thailand. AIDS 2007; 21 (Suppl 4):S105-S116.
35. Ghate MV, Tripathy SP, Kumar BK, et al. Rate of hospitalization and inpatient care costs for HIV-1-infected patients in Pune, India. Natl Med J India 2006; 19:10-14.
36. John KR, Rajagopalan N, Madhuri KV. Brief communication: economic comparison of opportunistic infection management with antiretroviral treatment in people living with HIV/AIDS presenting at an NGO clinic in Bangalore, India. Med Gen Med 2006; 8:24.
37. Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and costeffectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21 (Suppl 4):S117-S128.
38. Dandona L, Kumar SG, Ramesh YK, et al. Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India. BMC Health Serv Res 2008; 8:26.
39. Paton NI, Chapman CAT, Sangeetha S, et al. Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore. Int J STD AIDS 2006; 17:699-705.
40. Decock RC, Depoorter AM, De Graeve D, Colebunders R. Direct costs of healthcare for HIV/AIDS patients in Belgium. AIDS Care 2001; 13:721-731.
41. Decock R, Depoorter A, De Graeve D. Total costs of health services for HIV/AIDS patients in Belgium. Adv Psychol Res 2003; 23:45-59.
42. Peyron F, Rahmouni S, Flori A, et al. Impact of protease inhibitors on drug use and cost for hospital patients with HIV. J Pharm Technol 1999; 15:212-218.
43. Chaix C, Grenier-Sennelier C, Clevenbergh P, et al. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J Acquir Immune Defic Syndr 2000; 24:227-231.
44. Flori YA, le Vaillant M. Use and cost of antiretrovirals in France 1995-2000: an analysis based on the medical dossier on human immunodeficiency (release 2) database. Pharmacoeconomics 2004; 22:1061-1070.
45. Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther 2002; 7:257-266.
46. Le Pen C, Rozenbaum W, Downs A, et al. A cost-effectiveness analysis of changes in therapeutic strategies in the treatment of HIV since 1996. Therapie 2002; 57:27-33. (Pubitemid 34578649)
47. Basuyau F, Josset V, Merle V, Czernichow P. Case fatality and healthcare costs in HIV-infected patients: evolution from 1992 to 2000 at Rouen university hospital, France. Int J STD AIDS 2004; 15:679-684.
48. Charreau I, Jeanblanc G, Tangre P, et al., ANRS 106 Study Group. Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 window trial. J Acquir Immune Defic Syndr 2008; 49:416-421.
49. Stoll M, Claes C, Schulte E, et al. Direct costs for the treatment of HIVinfection in a German cohort after the introduction of HAART. Eur J Med Res 2002; 7:463-471.
50. Kyriopoulos JE, Geitona MA, Paparizos VA, et al. The impact of new antiretroic therapeutic schemes on the cost for AIDS treatment in Greece. J Med Syst 2001; 25:73-80.
51. Heerey A, McGowan B, Ryan M, Barry M. Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoeconomics Outcomes Res 2002; 2:29-33.
52. Ryan M, Merry C, Ryan C, et al. Population based study of the cost of inpatient care for HIV-infected individuals in an Irish teaching hospital. Ir Med J 2004; 97:200-202.
53. 3). HIV Clin Trials 2000;1:9-16
54. Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care 2001; 13:733-741.
55. Torti C, Casari S, Palvarini L, et al. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy 2003; 65:261-267.
56. Tramarin A, Campostrini S, Postma MJ, et al. A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmacoeconomics 2004; 22:43-53.
57. Tramarin A, Postma MJ, Gerzeli S, et al. The clinical and economic efficacy of HAART: a shift from inpatient medical to outpatient pharmaceutical care for HIV/AIDS patients in northeastern Italy. AIDS Care 2004; 16:213-218.
58. Merito M, Bonaccorsi A, Pammolli F, et al. Economic evaluation of HIV treatments: the I.C.O.N. A. cohort study. Health Policy 2005; 74:304-313.
59. Hubben GA, Bos JM, Veltman-Starkenburg CA, et al. Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in The Netherlands. Cost Eff Resour Alloc 2007; 5:15.
60. Hubben GA, Bishai D, Pechlivanoglou P, et al. The societal burden of HIV/ AIDS in Northern Italy: an analysis of costs and quality of life. AIDS Care 2008; 20:449-455.
61. Rozenbaum MH, Verweel G, Folkerts DK, et al. Cost-effectiveness estimates for antenatal HIV testing in The Netherlands. Int J STD AIDS 2008; 19:668-675.
62. Velasco M, Gómez A, Fernández C, et al. Economic impact of HIV protease inhibitor therapy in the global use of health-care resources. HIV Med 2000; 1:246-251.
63. Velasco M, Losa JE, Espinosa A, et al. Economic evaluation of assistance to HIV patients in a Spanish hospital. Eur J Intern Med 2007; 18:400-404.
64. Lowy A, Page J, Jaccard R, et al. Costs of treatment of Swiss patients with HIV on antiretroviral therapy in hospital-based and general practice-based care: a prospective cohort study. AIDS Care 2005; 17:698-710.
65. Simcock M, Sendi P, Ledergerber B, et al. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Antivir Ther 2006; 11:305-314.
66. Beck E, Mandalia S, Parmar D, et al., for the NPMS-HHC Steering Group. Changing cost of English HIV service provision 1996-1997. Int J STD AIDS 1999; 10:357-362.
67. Beck EJ, Beecham J, Mandalia S, et al. What is the cost of getting the price wrong? J Public Health Med 1999; 21:311-317.
68. Davies D, Carne C, Camilleri-Ferrante C. Combined antiviral treatment in HIV infection. Is it value for money? Public Health 1999; 113:315-317.
69. Beck EJ, Mandalia S,Griffith R, et al. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre. Pharmacoeconomics; 17:53-69.
70. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2000; 14:335-342.
71. Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002). Int J STD AIDS 2008; 19:297-304.
72. Simpson KN, Jones WJ, Rajagopalan R, Dietz B. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral- experienced patients in the UK, France, Italy and Spain. Clin Drug Investig 2007; 27:807-817. (Pubitemid 350145434)
73. Anis AH, Guh D, Hogg RS, et al. The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics 2000; 18:393-404.
74. Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ 2001; 165:415-420.
75. Krentz HB, Auld MC, Gill MJ. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ 2003; 169:106-110.
76. Beck EJ,MandaliaS,GaudreaultM, et al.The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 2004; 18:2411-2418.
77. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4
78. Yeung H, Krentz HB, Gill MJ, Power C. Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. AIDS 2006; 20:2005-2009.
79. Podymow T, Turnbull J, Coyle D. Shelter-based palliative care for the homeless terminally ill. Palliat Med 2006; 20:81-86.
80. Nosyk B, Li X, Sun H, Anis AH. The effect of homelessness on hospitalisation among patients with HIV/AIDS. AIDS Care 2007; 19:546-553.
81. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Med 2008; 9:721-730.
82. Koenig SP, Riviere C, Leger P, et al. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 2008; 6:3. Annual cost of first-year and second-year on HAART in Haiti.
83. Lavalle C, Aguilar JC, Peña F, et al. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with AIDS treated with protease inhibitors. Arch Med Res 2000; 31:515-519.
84. Bautista-Arredondo S, Dmytraczenko T, Kombe G, Bertozzi SM. Costing of scaling up HIV/AIDS treatment in Mexico. Salud Publica Mex 2008; 50 (Suppl 4) S437-S444.
85. Keiser P, Kvanli MB, Turner D, et al. Protease inhibitor-based therapy is associated with decreased HIV-related healthcare costs in men treated at a veterans administration hospital. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:28-33.
86. Bentham WD, Cai L, Schulman KA. Characteristics of hospitalizations of HIV-infected patients: an analysis of data from the 1994 Healthcare Cost and Utilization Project. J Acquir Immune Defic Syndr 1999; 22:503-508.
87. Mole L, Ockrim K, Holodniy M. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US veterans affairs medical center. Pharmacoeconomics 1999; 16:307-315.
88. Mitchell JM, Anderson KH. Effects of case management and new drugs on Medicaid AIDS spending. Health Aff (Millwood) 2000; 19:233-243.
89. Lapins DL, Urdaneta ME, Barrett J, et al. Costs of care for HIV infection in a managed care population from 1995 to 1997. Am J Manag Care 2000; 6:973-981.
90. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIVinfected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344:817-823.
91. Goldman DP, Bhattacharya J, Leibowitz AA, et al. The impact of state policy on the costs of HIV infection. Med Care Res Rev 2001; 58:31-53; discussion 54-59.
92. Keiser P, Nassar N, Kvanli MB, et al. Long-term impact of highly active antiretroviral therapy on HIV-related healthcare costs. J Acquir Immune Defic Syndr 2001; 27:14-19.
93. Wong MT. HIV care in correctional settings is cost-effective and improves medical outcomes. Infect Dis Clin Pract 2001; 10:S9-S15.
94. Wallace MR, Tasker SA, Shinohara YT, et al. The changing economics of HIV care. AIDS Patient Care STDS 2001; 15:25-29.
95. Eichner J, Kahn J. Coordination of health coverage for Medicare enrollees: a case study of HIV/AIDS. Medicare Brief 2001; 8:1-12.
96. Becker S. Delivering cost-effective HIV patient care: the experience of a large San Francisco independent physician association. Infect Dis Clin Prac 2001; 10:S29-S32.
97. Keiser P. HIV-related costs in public hospital settings: impact of HAART. Infect Dis Clin Pract 2001; 10 (Suppl 3):S16-S19.
98. Merrill D. Aggressive management of HIV infections in an HMO setting. Infect Dis Clin Pract 2001; 10:S20-S24.
99. Caro JJ, O'Brien JA, Migliaccio-Walle K, Raggio G. Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy. Pharmacoeconomics 2001; 19:95-104.
100. Kim YK, Stoskopf CH, Glover SH. Factors affecting total hospital charges and utilization for South Carolina inpatients with HIV/AIDS in 1994-1996. AIDS Patient Care STDS 2001; 15:277-287.
101. Brown MJ, Eastman M, Shenassa ED. Changing trends of HIV-related hospitalizations: a small area analysis in Illinois, 1994-2000. J Commun Health 2003; 28:247-255.
102. Rothbard AB, Metraux S, Blank MB. Cost of care for Medicaid recipients with serious mental illness and HIV infection or AIDS. Psychiatr Serv 2003; 54:1240-1246.
103. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5:294-304.
104. Hellinger FJ. HIV patients in the HCUP database: a study of hospital utilization and costs. Inquiry 2004; 41:95-105.
105. Anderson K, Mitchell J. AIDS home- and community-based waivers: effects on use of services, expenditures, and survival. South Econ J 2004; 71:60-77.
106. Purdum AG, Johnson KA, Globe DR. Comparing total healthcare costs and treatment patterns of HIV patients in a managed care setting. AIDS Care 2004; 16:767-780.
107. Hellinger FJ, Encinosa WE. Antiretroviral therapy and healthcare utilization: a study of privately insured men and women with HIV disease. Health Serv Res 2004; 39:949-967.
108. Richter A, Pladevall M, Manjunath R, et al. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med 2005; 6:79-90.
109. Mauskopf J, Kitahata M, Kauf T, et al. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr 2005; 39:562-569.
110. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 2005; 43:III40-III52.
111. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990-997.
112. Sansom SL, Anderson JE, Farnham PG, et al. Updated estimates of healthcare utilization and costs among perinatally HIV-infected children. J Acquir Immune Defic Syndr 2006; 41:521-526.
113. Roberts RR, Kampe LM, Hammerman M, et al. The cost of care for patients with HIV from the provider economic perspective. AIDS Patient Care STDS 2006; 20:876-886.
114. Kourtis AP, Bansil P, Johnson C, et al. Children with sickle cell disease and human immunodeficiency virus-1 infection: use of inpatient care services in the United States. Pediatr Infect Dis J 2007; 26:406-410.
115. Chen RY, Accortt NA, Westfall AO, et al. Distribution of healthcare expenditures for HIV-infected patients. Clin Infect Dis 2006; 42:1003-1010.
116. Hill A, Gebo K. Predicting HIV care costs using CD4 counts from clinical trials. Am J Manag Care 2007; 13:524-528.
117. Zaller N, Thurmond P, Rich JD. Limited spending: an analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners. Public Health Rep 2007; 122:49-54.
118. Hellinger FJ. The changing pattern of hospital care for persons living with HIV: 2000 through 2004. J Acquir Immune Defic Syndr 2007; 45:239-246.
119. Kourtis AP, Paramsothy P, Posner SF, et al. National estimates of hospital use by children with HIV infection in the United States: analysis of data from the 2000 KIDS inpatient database. Pediatrics 2006; 118:e167-e173.
120. Gilden DE, Kubisiak JM, Gilden DM. Managing Medicare's HIV caseload in the era of suppressive therapy. Am J Public Health 2007; 97:1053-1059.
121. Simpson KN, Luo MP, Chumney EC, et al. Cost effectiveness of lopinavir/ ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig 2007; 27:67-74.
122. Tencer T, Friedman HS, Li-McLeod J, Johnson K. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. J Manag Care Pharm 2007; 13:790-798.
123. Ettner SL, Conover CJ, Proescholdbell RJ, et al., HIV/AIDS treatment adherence, health outcomes and cost study group. Triply-diagnosed patients in the HIV/AIDS treatment adherence, health outcomes and cost study: patterns of home care use. AIDS Care 2008; 20:1177-1189.
124. Gardner EM, Maravi ME, Rietmeijer C, et al. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy 2008; 6:145-155.
125. Gilman BH, Green JC. Understanding the variation in costs among HIV primary care providers. AIDS Care 2008; 20:1050-1056. Annual cost of US patients seen in early intervention services (EIS) program.
126. Hellinger FJ, Encinosa WE. Inappropriate drug combinations among privately insured patients with HIV disease. Med Care 2005; 43:III-53-III-62.
127. Mandalia S, Lo Gary, Chadborn T, et al. Rising population cost for treating HIV patients in the NHS 1997-2006, Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH) 20-23 April 2010, Manchester, UK Abstract P278.
128. Morris K. New WHO guidelines on antiretrovirals welcomed worldwide. Lancet Infect 2010; 10:11-12.
129. Severe P, Pape J, Fitzgerald DW, et al. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T cell count of 200-350 cells/ml (CIPRAHT001)', ICAAC 2009; abstract H- 1230c. http://www.ceitraining.org/icaac-update/ (Accessed January 2010).
130. Hecht R, Bollinger L, Stover J, et al. Critical choices in financing the response to the global HIV/AIDS pandemic. Health Affairs 2009; 28:1591-1605.
131. Roberts RA, Hickey A, Rosner Z. The role of community involvement in HIV programmes in South Africa. In: Beck EJ, Mays N, Whiteside A, Zuniga J, editors. The HIV pandemic: local and global implications. Oxford: Oxford University Press; 2006. pp. 720-733.
132. WHO. National Health Accounts (NHA). Geneva: World Health Organization. http://www.who.int/nha/en/. [Accessed January 2010]
133. UNAIDS. National AIDS Spending Assessment (NASA): a notebook on methods, definitions and procedures for the measurement of HIV and AIDS financing flows and expenditures at country level. Version 21. Geneva: UNAIDS; 2006.
134. Beck EJ, Blandford J, Boulle A, et al. Essential information for countries to monitor and evaluate the economic aspects of HIV service provision. In: Proceedings from WHO/TDR Generic Tools Workshop; 16-18 January 2006; Geneva. http://www.who.int/hiv/events/GenericToolsWorkshop.pdf. [Accessed January 2010]